Mumps, Human, IgG, BioAssay(TM) ELISA Kit

Mumps, Human, IgG, BioAssay(TM) ELISA Kit is intended for the detection and quantitative determination of IgG antibody to Mumps virus in human sera. Individual serum specimens may be used for the determination of immune status. Paired sera, acute and convalescent, may be used to demonstrate seroconversion or a significant rise in antibody.\n\nThe mumps virus is a member of the paramyxovirus group and the etiological agent of mumps in man. Mumps is a generalized illness usually accompanied by parotid (salivary gland) swelling and mild symptoms. It is also one of the most common causes of aseptic meningitis, encephalitis, and inflammation of the testes (orchitis), pancreas, and ovaries.\n\nParotitis as a presenting symptom in mumps infections is usually sufficiently diagnostic to preclude serological confirmation. However, a third of mumps infections are subclinical or unrecognized and may require viral isolation and/or some other serological procedure to confirm or rule out mumps infection. An example of this is presenting orchitis or meningoencephalitis, the two most common complications of mumps infection, without salivary gland involvement.Virus isolation is time consuming and cumbersome and is usually an impractical procedure for the typical clinical laboratory. Current methods for serodiagnosis of mumps infections are in-vitro serum neutralization, hemagglutination-inhibition (HAI), indirect immunofluorescence, and complement fixation (CF) tests. Of these methods, neutralization is reportedly the most specific. However, the neutralization test requires 4-5 days to complete the test. HAI and CF are reportedly less sensitive than the neutralization test.These methods lack specificity, which limits their usefulness in determining immune status. The HAI test also requires pretreatment of test serum to remove nonspecific hemagglutination inhibitors from some serum.\n\nInfection with mumps virus, whether symptomatic or subclinical, is generally thought to offer lifelong immunity.\n\nAs first described by Engvall and Perlman and Van Weeman, ELISAs can be both specific and sensitive for the detection and measurement of serum proteins. The sensitivity, specificity, and reproducibility of enzyme-linked immunoassays can be comparable to other serological tests for antibody, such as immunofluorescence, complement fixation, hemagglutination and neutralization.\n\nELISA is as sensitive as the neutralization test and more sensitive than CF and HAI which makes it a reliable test for determination of immune status. The United States Biological Mumps, Human, IgG, BioAssay(TM) ELISA Kit provides all the necessary reagents for the rapid determination and quantitation of IgG antibody to mumps virus in sample serum.\n\nKit Components:\n1. Microtiter Plate, Mumps virus antigen (inactivated): 1 X 96 wells\n2. Serum Diluent: 1X30ml\n3. Calibrator (sample serum or defibrinated plasma): 1X400ul\n4. Positive Control: 1X400ul\n5. Negative Control: 1X400ul\n6. IgG (HRP) Goat x human: 1X16ml\n7. Tetramethylbenzidine (TMB): 1x15ml \n8. Wash Buffer, 20X: 1x50ml\n9. Stop Solution: 1x15ml (1N H2SO4)\n\nStorage and Stability:\nStore all components at 4 degrees C. Stable for 6 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

M9215-04

Size

1Kit

Applications

ELISA

Reactivities

Hum

References

1. Kleiman, M. B. 1985. Mumps Virus Infections. In: Laboratory Diagnosis of Viral Infections, E. H. Lennette, ed. Dekker, New York. 23: 369-384. 2. Engvall, E., K. Jonsson, and P. Perlman. 1971. Enzyme Linked Immunosorbent Assay, (ELISA) Quantitative Assay of Immunoglobulin G. Immunochemistry. 8: 871-874. 3. Engvall, E. et al., Pergamon Press. pp. 553-556. 4. Engvall, E., et al., Biochem. Biophys. Acta. 251: 427-434. 5. Van Weeman, B. K. and A.H.W.M. Schuurs. 1971. Immunoassay Using Antigen-Enzyme Conjugates. FEBS Letter. 15: 232-235. 6. Bakerman, S. 1980. Enzymed Immunoassays. Lab. Mgmt. August: 21-29. 7. Voller, A., D. Bidwell, and A. Bartlett. 1976. In: Manual of Clinical Immunology, N. Rose, and H. Friedman, eds. pp. 505- 512. 8. Voller, A., D. Bidwell, and A. Bartlett. 1976. Bull. Wld. Hlth. Org. 53: 55-65. 9. Engvall, E. et al., J. Immunol. 109: 129-135. 10. CDC-NIH Manual. 1993. In: Biosafety in Microbiological and Biomedical Laboratories, 3rd Edition. U. S. Dept. of Health and sample Services, Public Health Service. pp 9-12. 11. National Committee for Clinical Laboratory Standards. 1990. Procedures for the Collection of Diagnostic Blood Specimens by Venipuncture Approved Standard. NCCLS Publication H18-A. 12. NCCLS. 1991. National Committee for Clinical Laboratory Standard. Internal Quality Control Testing: Principles & Definition. NCCLS Publication C24- A. 13. http://www.cap.org/html/ftpdirectory/ checklistftp.html. 1998. Laboratory General - CAP (College of American Pathology) Checklist (April 1998). pp 28-32. 14. NCCLS. 1997. National Committee for Clinical Laboratory Standard. Preparation and Testing of Reagent Water in the Clinical Laboratory. NCCLS Publication C3- A3.